NED-170
Cancer (specific types not fully specified)
Phase 1Active
Key Facts
About NED Biosystems
NED Biosystems is pioneering a novel systems-based therapeutic approach to treat complex diseases like cancer and viral infections by combining repurposed, oral drugs at non-toxic doses. Its lead asset, NED-170, is in development for cancer, while NED-260 is a platform-derived program aimed at being a universal antiviral. As a private, pre-revenue Public Benefit Corporation, the company is driven by a mission of global patient access and is led by founder/CEO Rebecca Lambert, supported by a seasoned team and scientific advisory board.
View full company profile